Carbonic Anhydrase IX/CA9 Antibody - BSA Free

CA9 expressed in hypoxic regions as assessed by pimonidazole staining (A), but also observed in non-pimonidazole areas (B). Most of CA9 expressed in pimonidazole positive regions (C). Proliferation (BrdUrd) & apoptosis (caspase-3) in relation to CA9 expression shown in figure D & E. Red, CA9; Green, pimonidazole (A-B), BrdUrd (D) or caspase-3 (E); Yellow, overlap of CA9 (red) & pimonidazole (green); Light blue, vessels. Magnification 100x. Scale bars represent 100 um. Closed circles represent CA9 expression in pimonidazole positive regions; open circles represent CA9 expression in pimonidazole -ve regions. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0108068), licensed under a CC-BY license.

Formalin-fixed paraffin-embedded tissue sections of human stomach were probed for Carbonic Anhydrase IX/CA9 mRNA (ACD RNAScope Probe, catalog # 559348; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus catalog # NB100-417) at 1:1000 dilution with overnight incubation at 4 degrees Celsius followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to glandular cells.

Analysis on various human cell lysates. Specific bands were detected for Carbonic Anhydrase IX/CA9 in HEK-293 and A498 cell lines at a molecular weight of approximately 50 kDa. WB image submitted by a verified customer review.

Immunohistochemical representative microphotographs representing the HIF-1alpha, GLUT-1, and CAIX expression in endometrial cancer according to FIGO classification (IA, IB, II, IIIA, IIIC, and IV). Primary objective magnification 20x. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2014/616850/) licensed under a CC-BY license.

Hypoxias impact on proteins of the mitochondrial ISC assembly machinery. (A) Immunoblotting analyzed the total protein extracts from HeLa cells grown in normoxia (Nx, 21% O2) or hypoxia (Hx, 1% O2) conditions using VDACs poly antibody and anti-CAIX, -ISCU, -FXN, -NFS1, -HSC20 antibodies. Beta-Actin was used as loading control. Citation: Ferecatu I, Canal F, Fabbri L, Mazure NM, Bouton C, Golinelli-Cohen M-P (2018) Dysfunction in the mitochondrial Fe-S assembly machinery leads to formation of the chemoresistant truncated VDAC1 isoform without HIF-1 alpha activation. PLoS ONE 13(3): e0194782.

Analysis using the DyLight 488 conjugate of NB100-417. Staining of Carbonic Anhydrase IX (red) in human glioma U87 cells. DAPI counterstains nuclei (blue). ICC/IF image submitted by a verified customer review.

Simple Western lane view shows a specific band for CAIX in 0.1 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

An intracellular stain was performed on U-87 MG Cells with NB100-417 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG APC-conjugated Secondary Antibody, (R&D Systems, F0111).

Western Blot analysis of Carbonic Anhydrase IX/CA9 Antibody on human breast cancer MCF7 cells. Image from verified customer review.

A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Carbonic Anhydrase IX/CA9 Antibody NB100-417 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.

An intracellular stain was performed on A431 cells with Carbonic Anhydrase IX/CA9 Antibody NB100-417 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).

Analysis in 1) HeLa, 2) MDA-MB-231, and 3) A549 whole cell lysates. Specific bands were detected for Carbonic Anhydrase IX/CA9 at a molecular weight of 50 kDa.

Analysis on rat renal cortex. A specific band was detected at a molecular weight of approximately 50 kDa.

Immunocytochemical analysis of CNHCs with antibodies against the RCC marker CAIX. Clusters of CNHCs cytomorphologically classified as uncertain malignant (-UMF) with cytoplasmic positive staining with antibodies against the RCC marker CAIX. Image collected and cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-11-214) licensed under a CC-BY license.

Analysis of human colon carcinoma, xenografted in mice. IHC-Fr image submitted by a verified customer review.

IHC analysis of a FFPE tissue section of human breast cancer using CAIX antibody at 1:1000 dilution. The primary antibody bound to CAIX antigens in the tissue section was detected using a HRP labeled secondary antibody and DAB reagent. Nuclei of the cells were counterstained with hematoxylin. This CAIX antibody generated an expected cytoplasmic staining of CAIX protein with an intense signal around the cellular membranes in tumor cores. The latter are more likely to be hypoxic in growing tumors which signifies that the observed CAIX staining is specific.

Strong cytoplasmic and membranous CA9 staining in glandular cells of human stomach tissue. Citrate buffer pH 6 antigen retrieval. Antibody at 1:250 dilution and detected with an Alexa Fluor 546 labeled goat-anti-rabbit secondary antibody. Nuclei detected with DAPI. IHC-P image submitted by a verified customer review.

Immunofluorescence of human RCC tumor cryosections using NB100-417 (Panel A). Panel B shows staining with normal rabbit serum.

Colorectal cancer xenograft growth was suppressed by CB-PIC(20 and 50 mg/kg body weight) in female athymic nude mice. Starting three days after SW620 cell inoculation, CB-PIC (20 and 50 mg/kg body weight) was injected in abdomen with 4% Tween 20 as vehicle once daily. Representative examples of immunohistochemical staining for CA IX in tumor section. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/ecam/2013/974313/), licensed under a CC-BY license.

Iron depletion and nitric oxide stress and Iron depletion induce the truncated VDAC1 form accumulation. (D) Total protein extracts were analyzed by immunoblotting using VDACs poly antibody and anti-HIF-1 alpha and -CAIX antibodies. (E) Immunoblotting was used to analyze total protein extracts using antibodies against the three VDAC isoforms. (F) HeLa cells were grown in hypoxia (Hx, 1% O2) conditions and transfected with iscu- or NC-siRNA for 3 days, or grown in normoxia (Nx, 21% O2), some treated with DFO for 16 h. Western Blots analyzed total proteins using VDACs poly antibody and anti-HIF-1 alpha, -CAIX, -ISCU antibodies. Citation: Ferecatu I, Canal F, Fabbri L, Mazure NM, Bouton C, Golinelli-Cohen M-P (2018) Dysfunction in the mitochondrial Fe-S assembly machinery leads to formation of the chemoresistant truncated VDAC1 isoform without HIF-1 alpha activation. PLoS ONE 13(3): e0194782.

Immunohistochemical representative microphotographs representing the HIF-1 alpha , GLUT-1, and CAIX expression in endometrial cancer according to FIGO classification (IA, IB, II, IIIA, IIIC, and IV). Primary objective magnification 20x.

The images are representative of immunohistochemistry staining of nuclear staining of proliferation marker Ki67, membrane protein CD 44, and CA IX. The images of scaffold culture (left panel) are compared with cell pellet paraffin section (right panel). The scaffold dissolved in xylene presented as a clear region marked ∗. All scale bars are 100 μm, magnification 40x.

Chemosensitivity of the CTC SCLC lines (IC50, mean ± SD) and immunohistochemistry of sections of tumorospheres. All differences between single cells (SC) and tumorospheres (TS) are statistically significant. Immunohistochemical staining of sections of UHGc5, BHGc16 and BHGc26 CTCs was performed using antibodies directed to CD56, CHGA, CAIX and Ki67, respectively.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Analysis of protein levels of genes with increased transcription in hypoxia, IOX2 & VH032.HIF targets were increased in hypoxia, VH298 & FG-4592. 0.05% DMSO (vehicle control), 1% O2 (hypoxia), 100 µM VH298 & 50 µM FG-4592 were introduced to (A) HeLa or HFF for 24 hours & (B) HeLa for indicated time. Protein levels were analysed by immunoblotting using antibodies against indicated proteins, with beta -Actin as loading control. The blots shown are representative of three independent experiments. * indicates longer exposure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30801039), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry-Paraffin: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - IGF1R & CA9 expression in PDAC.(A) Representative staining of CA9 cells quantified on a scoring system of 0–3 according to staining intensity (original magnification ×200). CA9 was mainly expressed in the cell membrane of PDAC cells. (B) IGF1R was mainly expressed in the cytoplasm of PDAC cells. (C) Association between IGF1Rexpression & CA9 expression in 120 pancreas cancer. A significant correlation was found between IGF1R expression level was significantly correlated with CA9 expression in PDAC cells (p < 0.01, rs = 0.649; Spearman’s rank sum test). The size of circle indicates the number of PDAC patients. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27487118), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Representative human colorectal cancer specimen. Immunohistochemistry of CA9 & GGT1 in mLNs. In these cases, both CA9 & GGT1 were expressed, suggesting that GGT1 expression is related to hypoxia in mLNs. Scale bar, 500 μm. Black arrowheads: GGT of cancer cells, white arrowheads: GGT surrounding cancer cells, arrow: accumulation of GGT. mLNs: metastatic lymph nodes, GGT: gamma-glutamyl transpeptidase. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30542087), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Representative microscopy images of staining for hypoxia markers in prostate tissues (MO, 400×). A) HIF-1 alpha - notice the granular cytoplasmic immunoreactivity of the malignant epithelial cells. In this case, more than 50% of the glands stained. B) LOX - strong & diffuse nuclear immunoreactivity of the epithelial cells. C) CAIX - note a focal apical cytoplasmic immunoreactivity in epithelial cells. D) VEGFR2 - moderate nuclear & weak cytoplasmic expression of the epithelial cells Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28143503), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - The images are representative of immunohistochemistry staining of nuclear staining of proliferation marker Ki67, membrane protein CD 44, & CA IX. The images of scaffold culture (left panel) are compared with cell pellet paraffin section (right panel). The scaffold dissolved in xylene presented as a clear region marked ∗. All scale bars are 100 μm, magnification 40x. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24101930), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Hypoxia, blood vessel & proliferation staining. IHC staining in the Biopsy 23 & Biopsy 3 respectively for CA-9, EF5, CD31, Ki67 & LYVE1. 15× Magnification. Image collected & cropped by CiteAb from the following publication (//www.mdpi.com/2072-6694/4/3/821), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - VH298 elicits a HIF-dependent hypoxic response in various cell lines.1% DMSO, hypoxia (1% O2) & indicated compounds at 100 μM were introduced to (a) HFF, HeLa, U2OS & (b) RCC4 cells expressing HA-tagged VHL (with the exception of cis-VH298 & VH298 used at 150 μM) for 24 h & (c) CTLs for 8 h. Protein levels were analysed by immunoblotting using antibodies against the indicated proteins, with beta -actin (SMC1 for CTLs) as the loading control. The blots shown are representative of three independent experiments. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27811928), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - HE staining & immunohistochemistry (CA9 & GGT1) of fixed primary tumor & mLN specimens from orthotopic mouse model. CA9 & GGT1 were expressed inside the primary tumor & in mLNs. GGT1 was accumulated in the area of central necrosis. HE: hematoxylin-eosin. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30542087), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Analysis of protein levels of genes with increased transcription in hypoxia, IOX2 & VH032.HIF targets were increased in hypoxia, VH298 & FG-4592. 0.05% DMSO (vehicle control), 1% O2 (hypoxia), 100 µM VH298 & 50 µM FG-4592 were introduced to (A) HeLa or HFF for 24 hours & (B) HeLa for indicated time. Protein levels were analysed by immunoblotting using antibodies against indicated proteins, with beta -Actin as loading control. The blots shown are representative of three independent experiments. * indicates longer exposure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30801039), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Comparison between primary tumor & mLNs of the mouse model. Expression of CA9 & GGT1 in mLNs was higher than that in the primary tumor at 1week after injection of cells. (A) CA9 & GGT1 expression of HT29 mLNs compared to primary tumor at 6 weeks or 1 week after injection of cells. (B) Tissue oxygen concentration (%) of rectal submucosa (SM) & nLNs (n = 3). Error bars represent SD. mNs: metastatic lymph nodes, nLNs: non metastatic lymph nodes. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30542087), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Chemosensitivity of the CTC SCLC lines (IC50, mean ± SD) & immunohistochemistry of sections of tumorospheres. All differences between single cells (SC) & tumorospheres (TS) are statistically significant. Immunohistochemical staining of sections of UHGc5, BHGc16 & BHGc26 CTCs was performed using antibodies directed to CD56, CHGA, CAIX & Ki67, respectively. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-017-05562-z), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Analysis of protein levels of genes with increased transcription in hypoxia, IOX2 & VH032.HIF targets were increased in hypoxia, VH298 & FG-4592. 0.05% DMSO (vehicle control), 1% O2 (hypoxia), 100 µM VH298 & 50 µM FG-4592 were introduced to (A) HeLa or HFF for 24 hours & (B) HeLa for indicated time. Protein levels were analysed by immunoblotting using antibodies against indicated proteins, with beta -Actin as loading control. The blots shown are representative of three independent experiments. * indicates longer exposure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30801039), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Immunocytochemical analysis of CNHCs with antibodies against the RCC marker CAIX. Clusters of CNHCs cytomorphologically classified as uncertain malignant (−UMF) with cytoplasmic positive staining with antibodies against the RCC marker CAIX (A). Clusters of CNHC-UMF & -BF without reactivity for CAIX antibodies (B & C, respectively). A single CNHC-MF with positive cytoplasmic (D) & without staining for CAIX (E). Single CAIX-negative CNHC-UMF & -BF (F & G, respectively). Image collected & cropped by CiteAb from the following publication (//translational-medicine.biomedcentral.com/articles/10.1186/1479-5876-11-214), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - GPRC5A promotes hypoxic cell survival via YAPAHypoxia induced increased total YAP expression in a panel of colorectal cancer cell lines. Actin confirmed equal loading; blots are representative of at least two independent experiments. Related to Fig 4.B–EqRT–PCR analysis revealed that hypoxia increased the expression of known YAP target genes AREG, BCL2L1 (BCL‐XL), CTGF & CYR61. Representative experiments are shown. Representative examples of n = 3 independent experiments are shown; data are presented as mean ± SD.FIncreased expression of YAP Ser397 in GPRC5A‐depleted cells was overridden by expression of constitutively active RhoA (G14V) in hypoxia. Expression of dominant negative RhoA (T19N) did not further increase YAP Ser397 phosphorylation in response to GPRC5A depletion.GDarker exposure of the GPRC5A blot in Fig 4I, confirming expression of 30–40 kDa & 80 kDa species. Note that YAP siRNA partially diminishes GPRC5A in line with the existence of positive HIF‐GPRC5A‐YAP feedback loop. Asterisk (*) indicates non‐specific band.Source data are available online for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30143543), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - CAIX expression in PDAC & association with outcomeA. Representative images of immunohistochemical staining showing: negative expression of CAIX in both tumor cell & stromal compartments (top left), positive expression of CAIX in tumor cells but not stromal compartment (top right), positive expression of CAIX in stromal compartment but not tumor cells (bottom left), positive expression of CAIX in both tumor cell & stromal compartments (bottom right). B. Kaplan-Meier analysis of CAIX expression in the distinct tumor cell & stromal compartments & the associated overall survival. C. Representative images of immunohistochemical staining showing low stromal volume & high stromal volume & low & high microvessel density D. Representative images of immunohistochemical staining showing: positive expression of MCT4 in tumor cell compartment & positive expression of MCT4 in tumor stromal compartment. Kaplan-Meier analysis of combinatorial MCT4 & CAIX expression in the stromal compartment & the associated overall survival. Hazard ratios & p-values for each comparison are summarized in the table. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Hypoxia & autophagy markers in breast cancer stem-cells(A) Co-expression of CD133 & BECLIN1 in pCR & non-pCR patients. Double IF X800. (B) Tumor cells (T) distributed around necrosis (N) express LC3B with typical cytoplasmic punctuated staining, ×1000. Double IF shows that some CD133-positive tumor cells co-express LC3B. ×400. (C) Tumor cells (T) distributed around necrosis (N) express CAIX, on their cytoplasmic membrane, ×1000. Double IF shows a co-expression of LC3B & CAIX in some tumor cells. ×400. (D) Laser microdissection of CD133-positive cells. (E) Laser-microdissected CD133-positive cells express PROMININ & not PTPRC (CD45). (F) mRNA relative quantification of HIF1A, CAIX, LC3B, BECN1, & BNIP3L show a significantly higher expression level in CD133-positive cells versus CD133-negative cells, in the 35 non-pCR biopsies. *p < 0.05. (G) Multivariate analysis of tumor cell characteristics & pCR shows an inverse correlation between pCR & cells bearing markers of stemness or autophagy. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28445132), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Immunofluorescent images showing CAIX expression, pimonidazole, apoptosis & proliferation in SCCNij202.CAIX is expressed in hypoxic regions as assessed by pimonidazole staining (A), but is also observed in non-pimonidazole areas (B). Yet, most of CAIX is expressed in pimonidazole positive regions (C). Proliferation (BrdUrd) & apoptosis (caspase-3) in relation to CAIX expression are shown in figure D & E respectively. Red, CAIX; Green, pimonidazole (A–B), BrdUrd (D) or caspase-3 (E); Yellow, overlap of CAIX (red) & pimonidazole (green); Light blue, vessels. Magnification 100×. Scale bars represent 100 µm. Closed circles represent CAIX expression in pimonidazole positive regions; open circles represent CAIX expression in pimonidazole negative regions. Abbrevations: 1× S4, 8 h, one i.p. injection S4, harvest after 8 hours; 1× S4, 24 h, one i.p. injection S4, harvest after 24 hours; 3× S4, one i.p. injection S4 a day for 3 days, harvest 8 hours after the last injection; 5× S4, one i.p. injection S4 a day for 5 days, harvest 8 hours after the last injection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25225880), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Colorectal cancer xenograft growth was suppressed by CB-PIC(20 & 50 mg/kg body weight) in female athymic nude mice. Starting three days after SW620 cell inoculation, CB-PIC (20 & 50 mg/kg body weight) was injected in abdomen with 4% Tween 20 as vehicle once daily. (a) Body weights of mice. (b) Tumor growth in a time course. (c) Final tumor weight at termination of experiment. (d) Representative examples of immunohistochemical staining for Ki-67, CD34, TUNEL, CA IX & pAMPK alpha in tumor sections. Graphs show the Ki67 index (proliferation), CD34 index (angiogenesis), TUNEL index (apoptosis), CA IX (hypoxia region), & pAMPK alpha index in tumor sections. Values are means ± SD, n = 6. *P < 0.05 & ***P < 0.001 compared with control mice. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23589723), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Hypoxia induces GPRC5A directly via HIFsASILAC‐based proteomics data identify known (red) & novel (green) hypoxia‐induced proteins in SW620 cells. One‐sample t‐test was performed.BWestern blotting confirmed GPRC5A as a hypoxia‐induced protein in SILAC lysates.CValidation of GPRC5A Western blot data using siRNA. *Non‐specific band of ˜60 kDa not depleted by GPRC5A siRNA.DConfocal microscopy showing plasma membrane GPRC5A expression in hypoxic SW620 cells (scale bars: 75 μm).EWestern blotting showing GPRC5A upregulation by hypoxia in a panel of colorectal tumour cell lines.FBasal & hypoxia‐induced GPRC5A protein expression was decreased by HIF‐1/2 alpha depletion.GDepletion of HIF‐1 beta decreased GPRC5A protein upregulation in hypoxia.HHypoxia mimetic DMOG induced HIF‐1/2 alpha , CA9 & GPRC5A protein expression. Dual HIF‐1/2 alpha depletion reduced GPRC5A induction by DMOG.IqRT–PCR demonstrating that GPRC5A mRNA was upregulated by hypoxia (n = 3). GPRC5A was normalised to HPRT (error bars ± SD).JqRT–PCR demonstrating that HIF‐1/2 alpha depletion decreased GPRC5A induction during hypoxia (n = 3). GPRC5A was normalised to HPRT (error bars ± SD).KChIP‐PCR analyses identify HIF‐1 alpha binding to the GPRC5A promoter region containing a putative optimal HRE (error bars ± SD, n = 3).Data information: Asterisks (*) indicate non‐specific band. Level adjustments were made to images in Adobe Photoshop post‐acquisition for clarity (equal changes applied to the entire image). Representative examples of n = 3 independent experiments are shown.Source data are available online for this figure. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30143543), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Immunofluorescent images showing CAIX expression, pimonidazole, apoptosis & proliferation in SCCNij202.CAIX is expressed in hypoxic regions as assessed by pimonidazole staining (A), but is also observed in non-pimonidazole areas (B). Yet, most of CAIX is expressed in pimonidazole positive regions (C). Proliferation (BrdUrd) & apoptosis (caspase-3) in relation to CAIX expression are shown in figure D & E respectively. Red, CAIX; Green, pimonidazole (A–B), BrdUrd (D) or caspase-3 (E); Yellow, overlap of CAIX (red) & pimonidazole (green); Light blue, vessels. Magnification 100×. Scale bars represent 100 µm. Closed circles represent CAIX expression in pimonidazole positive regions; open circles represent CAIX expression in pimonidazole negative regions. Abbrevations: 1× S4, 8 h, one i.p. injection S4, harvest after 8 hours; 1× S4, 24 h, one i.p. injection S4, harvest after 24 hours; 3× S4, one i.p. injection S4 a day for 3 days, harvest 8 hours after the last injection; 5× S4, one i.p. injection S4 a day for 5 days, harvest 8 hours after the last injection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25225880), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Immunofluorescent images showing CAIX expression, pimonidazole, apoptosis & proliferation in SCCNij202.CAIX is expressed in hypoxic regions as assessed by pimonidazole staining (A), but is also observed in non-pimonidazole areas (B). Yet, most of CAIX is expressed in pimonidazole positive regions (C). Proliferation (BrdUrd) & apoptosis (caspase-3) in relation to CAIX expression are shown in figure D & E respectively. Red, CAIX; Green, pimonidazole (A–B), BrdUrd (D) or caspase-3 (E); Yellow, overlap of CAIX (red) & pimonidazole (green); Light blue, vessels. Magnification 100×. Scale bars represent 100 µm. Closed circles represent CAIX expression in pimonidazole positive regions; open circles represent CAIX expression in pimonidazole negative regions. Abbrevations: 1× S4, 8 h, one i.p. injection S4, harvest after 8 hours; 1× S4, 24 h, one i.p. injection S4, harvest after 24 hours; 3× S4, one i.p. injection S4 a day for 3 days, harvest 8 hours after the last injection; 5× S4, one i.p. injection S4 a day for 5 days, harvest 8 hours after the last injection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25225880), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Establishment of a human protein replacement stable cell line using 47snoMEN.(a) Images of protein replacement stable cell lines (U2OSGFP–HIF-1 alpha -47PR). Expression of FP proteins was confirmed by fluorescence imaging with DFX treatment. Bar is 10 μm. (b) U2OS & U2OSGFP–HIF-1 alpha -47PR cells were exposed to 1% O2 for the indicated periods of time prior to lysis. Cell extracts were analysed by western blot using the indicated antibodies. (c) U2OS cells were transfected with 1 μg of control & HIF-1 alpha -47snoMEN vectors for 48 hours prior to lysis. DFX was added for the last 24 hours. Cell extracts were analysed by western blot using the indicated antibodies. (d) 3D culture analysis. HeLaGFP–HIF-1 alpha -47PR cells were cultured in lipidure coated plates to induce spheroid formation. HIF-1 alpha is visible in the core of the spheroid revealing hypoxia. Bar is 10 μm. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0154759), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody - BSA Free [NB100-417] - Immunofluorescent images showing CAIX expression, pimonidazole, apoptosis & proliferation in SCCNij202.CAIX is expressed in hypoxic regions as assessed by pimonidazole staining (A), but is also observed in non-pimonidazole areas (B). Yet, most of CAIX is expressed in pimonidazole positive regions (C). Proliferation (BrdUrd) & apoptosis (caspase-3) in relation to CAIX expression are shown in figure D & E respectively. Red, CAIX; Green, pimonidazole (A–B), BrdUrd (D) or caspase-3 (E); Yellow, overlap of CAIX (red) & pimonidazole (green); Light blue, vessels. Magnification 100×. Scale bars represent 100 µm. Closed circles represent CAIX expression in pimonidazole positive regions; open circles represent CAIX expression in pimonidazole negative regions. Abbrevations: 1× S4, 8 h, one i.p. injection S4, harvest after 8 hours; 1× S4, 24 h, one i.p. injection S4, harvest after 24 hours; 3× S4, one i.p. injection S4 a day for 3 days, harvest 8 hours after the last injection; 5× S4, one i.p. injection S4 a day for 5 days, harvest 8 hours after the last injection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25225880), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

• Reactivity: Hu, Mu, Rt, Pl
• Applications: WB, Simple Western, ELISA, Flow, Func, GS, ICC/IF, IHC, IP, MA, WB, ChIP, Dual ISH-IHC
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

Carbonic Anhydrase IX/CA9 Antibody - BSA Free Summary

• Immunogen: This Carbonic Anhydrase IX/CA9 Antibody was made from a synthetic peptide from the C-terminal sequence of human Carbonic Anhydrase IX (within residues 400-459) [UniProt# Q16790].
• Localization: Membrane.
• Marker: Hypoxia Marker
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: CA9
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Chromatin Immunoprecipitation (ChIP) 1:10-1:500
  • Dual RNAscope ISH-IHC 1:1000
  • ELISA reported in scientific literature (PMID 19963243)
  • Flow Cytometry 1:1000
  • Gel Super Shift Assays
  • Immunoblotting
  • Immunocytochemistry/ Immunofluorescence 2 - 5 ug/ml
  • Immunohistochemistry 1:200 - 1:500
  • Immunohistochemistry-Frozen 1:200 - 1:500
  • Immunohistochemistry-Paraffin 1:200 - 1:500
  • Immunoprecipitation 1:10 - 1:500. Use reported in multiple pieces of scientific literature
  • Microarray reported in scientific literature (PMID 31955345)
  • Proximity Ligation Assay
  • Simple Western 1:50
  • Western Blot 1 - 3 ug/ml
• Application Notes: In Western blot a band is observed approx. 53 kDa. In Simple Western only 10 - 15 uL of the recommended dilution is used per data point.
  See Simple Western Antibody Database for Simple Western validation: Tested in HeLa lysate 0.1 mg/mL, separated by Size, antibody dilution of 1:50, apparent MW was 65 kDa. Separated by Size-Wes, Sally Sue/Peggy Sue.
• Theoretical MW: 55 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• Control:

  HeLa Whole Cell Lysate
  Carbonic Anhydrase IX/CA9 Overexpression Lysate

• Control Peptide:

  Carbonic Anhydrase IX/CA9 Protein (NB100-417PEP)

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.02% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for Carbonic Anhydrase IX/CA9 Antibody - BSA Free

• CA9
• CAIX
• CA-IX
• Carbonate dehydratase IX
• carbonic anhydrase 9
• Carbonic Anhydrase IX
• carbonic dehydratase
• EC 4.2.1.1
• G250
• Membrane antigen MN
• MN
• P54/58N
• PMW1
• RCC
• RCC-associated antigen G250
• RCC-associated protein G250
• Renal cell carcinoma-associated antigen G250

Background

Carbonic anhydrase alpha, isozyme IX, belongs to a family of zinc-containing metalloproteins which hydrate carbon dioxide to generate bicarbonate ions and protons (1). This main catalytic function allows carbonic anhydrase IX to participate in cellular pH regulation. The large family of carbonic anhydrase metalloproteins includes three major classes which have been identified based on sequence and structure analysis. The alpha class is a monomer found in mammals. The beta class may occur as a dimer, tetramer, hexamer or octamer and is found in plants, algae, and bacteria. Lastly, the gamma class is a trimer found in bacteria and represents the most ancient carbonic anhydrase. These three classes of carbonic anhydrase enzymes lack sequence or structural similarities, but all share a conserved active site zinc atom (1).

Carbonic anhydrase IX (theoretical molecular weight 50kDa) belongs to the monomeric alpha class and is a single pass-transmembrane protein with two extracellular domains which serve catalytic and cell adhesion functions (2, 3). By cooperating with sodium bicarbonate cotransporters (NBC), lactate and proton exporting monocarboxylic acid transporters (MCT), and a sodium/hydrogen exchanger (NHE), carbonic anhydrase IX is involved in pH regulation across the cell membrane. This functional property protects cancer cells from intracellular acidification and partly explains the role of carbonic anhydrase IX in cancer cell survival and proliferation. In contrast, the pH regulating activity of carbonic anhydrase IX induces extracellular acidification, which has been implicated in epithelial to mesenchymal transition (EMT) and promoting cancer invasion. Carbonic anhydrase IX is frequently overexpressed in cancer cells (e.g., colorectal-, breast-, lung-carcinoma and brain tumors), an effect promoted by hypoxia within the tumor microenvironment (4). An exception are tumors carrying pVHL inactivating mutations, such as clear cell renal cell carcinoma (ccRCC), where HIF-alpha is stabilized due to dysfunctional proteasomal targeting and can induce HRE (Hypoxia Response Element) containing genes even under physiological normoxia (5). Carbonic anhydrase IX may be detected by immunostaining in tumors, which is found in association with necrotic tissue and metastatic cells. Because the expression of carbonic anhydrase IX correlates with both tumor grade and stage, analysis of its expression in tumors serves as a prognostic factor (4, 6).

References

1. Tripp, B. C., Smith, K., & Ferry, J. G. (2001). Carbonic Anhydrase: New Insights for an Ancient Enzyme. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.R100045200

2. Nishimori, I., & Onishi, S. (2001). Carbonic anhydrase isozymes in the human pancreas. Digestive and Liver Disease. https://doi.org/10.1016/s1590-8658(01)80138-9

3. Zavadova, Z., & Zavada, J. (2005). Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncology Reports. https://doi.org/10.3892/or.13.5.977

4. Pastorekova, S., & Gillies, R. J. (2019). The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer and Metastasis Reviews. https://doi.org/10.1007/s10555-019-09799-0

5. Haase, V. (2009). The VHL Tumor Suppressor: Master Regulator of HIF. Current Pharmaceutical Design. https://doi.org/10.2174/138161209789649394

6. Young, J. R., Coy, H., Kim, H. J., Douek, M., Sisk, A., Pantuck, A. J., & Raman, S. S. (2018). Association of the gross appearance of intratumoral vascularity at MDCT with the carbonic anhydrase IX score in clear cell renal cell carcinoma. American Journal of Roentgenology. https://doi.org/10.2214/AJR.18.19725

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Carbonic Anhydrase IX/CA9 Antibody (NB100-417)(292)

Publications using NB100-417

• Gabriella DH, Anbukkarasi M, Kamakshi S et al. Ref-1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF-1 alpha FASEB J. 2025-02-15 [PMID: 39902892] (Westen Blot, Mouse)
• Trentadue G, Kats-Ugurlu G, Blokzijl T et Al. Chronic Allograft Enteropathy Treated with Vedolizumab: A Case Report Transplant Proc 2024-12-04 [PMID: 39638713]
• Aubin RG, Montelongo J, Hu R, Gunther E et Al. Clustering-independent estimation of cell abundances in bulk tissues using single-cell RNA-seq data Cell Rep Methods 2024-11-19 [PMID: 39561717]
• Miklovicova S, Volpini L, Sanovec O et al. Mitochondrial respiratory complex II is altered in renal carcinoma. Biochimica et biophysica acta. Molecular basis of disease 2024-10-31 [PMID: 39486656]
• Suzuki S, Yashiro M, Izumi N et al. Impact of CA9 expression in the diagnosis of lymph-node metastases in non-small cell lung cancer based on [ 18 F]FDG PET/CT PLOS ONE 2024-10-29 [PMID: 39471162]
• Roos-Mattila M, Kallio P, Luck TJ et al. Distinct molecular profiles and shared drug vulnerabilities in pancreatic metastases of renal cell carcinoma Communications Biology 2024-10-20 [PMID: 39427059]
• Ge Z, Wang J, He L et al. Reconstruction of cancer marker analysis with holistic anatomical precision implicates heterogeneity development during breast tumor progression Discover Oncology 2024-10-15 [PMID: 39406984]
• Feodoroff M, Hamdan F, Antignani G et al. Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses Oncoimmunology 2024-09-25 [PMID: 39351443]
• Sewoom Baek, Hyun-Su Ha, Jeong Su Park, Min Jeong Cho, Hye-Seon Kim, Seung Eun Yu, Seyong Chung, Chansik Kim, Jueun Kim, Ji Youn Lee, Yerin Lee, Hyunjae Kim, Yujin Nam, Sungwoo Cho, Kyubae Lee, Ja Kyung Yoon, Jin Sub Choi, Dai Hoon Han, Hak-Joon Sung Chip collection of hepatocellular carcinoma based on O 2 heterogeneity from patient tissue Nature Communications 2024-06-15 [PMID: 38879551]
• Franzolin, G;Brundu, S;Cojocaru, CF;Curatolo, A;Ponzo, M;Mastrantonio, R;Mihara, E;Kumanogoh, A;Suga, H;Takagi, J;Tamagnone, L;Giraudo, E; PlexinB1 inactivation reprograms immune cells in the tumor microenvironment, inhibiting breast cancer growth and metastatic dissemination Cancer immunology research 2024-06-14 [PMID: 38874583]
• Ayelén M. Santamans, Beatriz Cicuéndez, Alfonso Mora, María Villalba-Orero, Sanela Rajlic, María Crespo, Paula Vo, Madison Jerome, Álvaro Macías, Juan Antonio López, Magdalena Leiva, Susana F. Rocha, Marta León, Elena Rodríguez, Luis Leiva, Aránzazu Pintor Chocano, Inés García Lunar, Ana García-Álvarez, Pablo Hernansanz-Agustín, Víctor I. Peinado, Joan Albert Barberá, Borja Ibañez, Jesús Vázquez, Jessica B. Spinelli, Andreas Daiber, Eduardo Oliver, Guadalupe Sabio MCJ: A mitochondrial target for cardiac intervention in pulmonary hypertension Science Advances 2024-01-19 [PMID: 38241373]
• Li H, Song C, Zhang Y et Al. Transgelin Promotes Glioblastoma Stem Cell Hypoxic Responses and Maintenance Through p53 Acetylation Adv Sci (Weinh) 2023-12-12 [PMID: 38087889]
• Massenet-Regad L, Poirot J, Jackson M et al. Large-scale analysis of cell-cell communication reveals angiogenin-dependent tumor progression in clear cell renal cell carcinoma iScience 2023-10-01 [PMID: 38025776] (IF/ICC, Human)
• Fantin J, Toutain J, Pérès EA et al. Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [64Cu][Cu(ATSM)] PET and proteomic studies EJNMMI research 2023-11-25 [PMID: 38006431] (IHC-Fr, Human)
• Sun X, Sui W, Mu Z et al. Mirabegron displays anticancer effects by globally browning adipose tissues Nature communications 2023-11-22 [PMID: 37993438] (IHC, Mouse)
• Rao H, Liu C, Wang A et al. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer Nature communications 2023-11-21 [PMID: 37989747] (IHC, Mouse)
• Imanishi M, Inoue T, Fukushima K et al. CA9 and PRELID2; hypoxia-responsive potential therapeutic targets for pancreatic ductal adenocarcinoma as per bioinformatics analyses Journal of Pharmacological Sciences 2023-12-01 [PMID: 37973221] (Western Blot, Human)
• Griesinger AM, Riemondy K, Eswaran N et al. Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma iScience 2023-09-15 [PMID: 37694144] (Immunohistochemistry-Paraffin, Human)
• Pearsall SM, Williamson SC, Humphrey S et al. Lineage plasticity in SCLC generates non-neuroendocrine cells primed for vasculogenic mimicry Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023-07-14 [PMID: 37455012] (WB)
  
  Details:
  Dilutions: 1:500
• Zwergel C, Aventaggiato M, Garbo S et al. Novel 1,4-Dihydropyridines as Specific Binders and Activators of SIRT3 Impair Cell Viability and Clonogenicity and Downregulate Hypoxia-Induced Targets in Cancer Cells Journal of Medicinal Chemistry 2023-07-27 [PMID: 37439550] (Immunohistochemistry-Paraffin, Human)
• Wu J, Jing X, Du Q et al. Disruption of the Clock Component Bmal1 in Mice Promotes Cancer Metastasis through the PAI-1-TGF-?-myoCAF-Dependent Mechanism Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023-06-17 [PMID: 37330661] (IHC-P, Mouse)
  
  Details:
  IHC-P: antibdy dilution: 1:200. Antigen retrieval: citrate-based solution pH 6.0 (H-3300, Vector)
• Vinciguerra A, Bedarida V, Pronier C et al. Expression, Prognostic Value and Correlation with HPV Status of Hypoxia-Induced Markers in Sinonasal Squamous Cell Carcinoma Journal of Personalized Medicine 2023-04-29 [PMID: 37240937] (IHC-P, Human)
• Aboouf MA, Armbruster J, Guscetti F et al. Endogenous myoglobin expression in mouse models of mammary carcinoma reduces hypoxia and metastasis in PyMT mice Scientific reports 2023-05-09 [PMID: 37161046] (Immunohistochemistry, Mouse)
• Aventaggiato M, Preziosi A, Cheraghi Bidsorkhi H et al. ZnO Nanorods Create a Hypoxic State with Induction of HIF-1 and EPAS1, Autophagy, and Mitophagy in Cancer and Non-Cancer Cells International journal of molecular sciences 2023-04-09 [PMID: 37108134] (WB, Human)
• Odeh S, Samarska I, Matoso A et al. Histologic re?evaluation of a population?based series of renal cell carcinomas from The Netherlands Cohort Study according to the 2022 ISUP/WHO classification Oncology Letters 2023-03-15 [PMID: 37033104] (Human)
• Glassman D, Kim MS, Spradlin M et al. Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer iScience 2023-02-17 [PMID: 36824283] (Immunohistochemistry-Paraffin, Human)
• Elliya Park, Lily Yi Li, Chunsheng He, Azhar Z. Abbasi, Taksim Ahmed, Warren D. Foltz, Regan O'Flaherty, Maham Zain, Robert P. Bonin, Andrew M. Rauth, Paul E. Fraser, Jeffrey T. Henderson, Xiao Yu Wu Brain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways Advanced Science 2023-02-19 [PMID: 36808713]
• Aubin RG, Montelongo J, Hu R, Camara PG Clustering-independent estimation of cell abundances in bulk tissues using single-cell RNA-seq data bioRxiv : the preprint server for biology 2023-02-07 [PMID: 36798206] (IHC-P, Human)
• Eloranta K, Pihlajoki M, Liljeström E et al. SLC-0111, an inhibitor of carbonic anhydrase IX, attenuates hepatoblastoma cell viability and migration Frontiers in oncology 2023-01-26 [PMID: 36776327] (WB)
• Mardente S, Aventaggiato M, Splendiani E et al. Extra-Cellular Vesicles Derived from Thyroid Cancer Cells Promote the Epithelial to Mesenchymal Transition (EMT) and the Transfer of Malignant Phenotypes through Immune Mediated Mechanisms International journal of molecular sciences 2023-02-01 [PMID: 36769076] (WB, Human)
• Ito R, Yashiro M, Tsukioka T et al. Usefulness of pyruvate dehydrogenase-E1? expression to determine SUVmax cut-off value of [(18)F]FDG-PET for predicting lymph node metastasis in lung cancer Scientific Reports 2023-01-28 [PMID: 36709375] (Immunohistochemistry-Paraffin, Human)
• Li Y, Lih TM, Dhanasekaran SM et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness Cancer cell 2022-12-20 [PMID: 36563681] (IHC-P, Human)
• Jing X, Wu J, Dong C et al. COVID-19 instigates adipose browning and atrophy through VEGF in small mammals Nature metabolism 2022-12-01 [PMID: 36482111] (IHC-P, WB, Mouse)
• Agudelo JP, Upadhyay D, Zhang D et al. Multiparametric Magnetic Resonance Imaging and Metabolic Characterization of Patient-Derived Xenograft Models of Clear Cell Renal Cell Carcinoma Metabolites 2022-11-15 [PMID: 36422257] (IHC-P, Human)
• Stirling ER, Terabe M, Wilson AS et al. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response Journal for immunotherapy of cancer 2022-11-01 [PMID: 36418073] (IHC-P, Mouse)
• Gong YY, Shao H, Li Y et al. Na(+)/H(+)-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells Cancer Research Communications 2022-11-16 [PMID: 36380966] (Immunohistochemistry-Paraffin, Human)
• De Filippis R, W�lflein G, Um IH et al. Use of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma Cancers (Basel) 2022-11-01 [PMID: 36358805] (Immunohistochemistry-Paraffin, Human)
• de Koster EJ, van Engen-van Grunsven ACH, Bussink J et al. [18F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules Molecular imaging and biology 2022-10-17 [PMID: 36253663]
• Liu Q, Stel WV, Noord VEV et al. Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells International Journal of Molecular Sciences 2022-09-04 [PMID: 36077517] (Immunohistochemistry-Paraffin, Human)
• Aoki T, Kinoshita J, Munesue S et al. Hypoxia-Induced CD36 Expression in Gastric Cancer Cells Promotes Peritoneal Metastasis via Fatty Acid Uptake Annals of Surgical Oncology 2023-05-01 [PMID: 36042102] (Immunohistochemistry-Paraffin, Human)
• Ye C, Li H, Li Y et al. Hypoxia-induced HMGB1 promotes glioma stem cells self-renewal and tumorigenicity via RAGE iScience 2022-09-16 [PMID: 36034219] (IHC-Fr, IHC-P, Human)
• Simmler P, Cortijo C, Koch LM et al. SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer Cell reports 2022-08-23 [PMID: 36001976] (WB)
• Seki T, Yang Y, Sun X et al. Brown-fat-mediated tumour suppression by cold-altered global metabolism Nature 2022-08-01 [PMID: 35922508] (IHC-P, Mouse)
  
  Details:
  Dilution: 1:300
• Steenbrugge J, Bellemans J, Vander Elst N et al. One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer OncoImmunology 2022-12-31 [PMID: 35898705] (Immunohistochemistry-Paraffin, Human)
• Bell HN, Kumar-Sinha C, Mannan R et al. Pathogenic ATM and BAP1 germline mutations in a case of early-onset, familial sarcomatoid renal cancer Cold Spring Harbor molecular case studies 2022-04-01 [PMID: 35483881] (IF/IHC)
• Kim JH, Nam JK, Kim AR et al. 2-Methoxyestradiol Inhibits Radiation-Induced Skin Injuries International journal of molecular sciences 2022-04-10 [PMID: 35456989] (IHC-P, Mouse)
• Zhang P, Liu G, Hu J et al. Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas Frontiers in Immunology 2022-03-16 [PMID: 35371015] (IF/IHC, Human)
• Ryniawec JM, Coope MR, Loertscher E et al. GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors Diagnostics (Basel, Switzerland) 2022-03-10 [PMID: 35328229] (ICC/IF, Human)
• Brereton CJ, Yao L, Davies ER et al. Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis eLife 2022-02-21 [PMID: 35188460] (IF/IHC, Human)
• Boizot J, Minville-Walz M, Reinhardt DP et al. FBN2 Silencing Recapitulates Hypoxic Conditions and Induces Elastic Fiber Impairment in Human Dermal Fibroblasts International journal of molecular sciences 2022-02-05 [PMID: 35163744] (ICC/IF, Human)
• Yelek C, Mignion L, Paquot A et al. Tumor Metabolism Is Affected by Obesity in Preclinical Models of Triple-Negative Breast Cancer Cancers (Basel) 2022-01-23 [PMID: 35158830] (Immunohistochemistry-Paraffin, Human)
• Chow E, Lau JSH, Wai T, Lam IPY. The anti-tumoral effects of the oxygen carrier YQ23 in a triple-negative breast cancer syngeneic model Translational Cancer Research 2021-02-01 [PMID: 35116399] (Immunohistochemistry-Paraffin, Human)
• Xie y, Sahin M, Sinha S et al. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes Nature cancer 2022-02-01 [PMID: 35115713]
• Westbrook RL, Bridges E, Roberts J et al. Proline synthesis through PyCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions Cell reports 2022-02-01 [PMID: 35108535] (IHC-P, Human)
• Wiechec E, Matic N, Ali A, Roberg K Hypoxia induces radioresistance, epithelial mesenchymal transition, cancer stem cell like phenotype and changes in genes possessing multiple biological functions in head and neck squamous cell carcinoma Oncology reports 2022-03-01 [PMID: 35059742] (WB)
• Wadsworth BJ, Lee CM, Bennewith KL Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts British journal of cancer 2022-01-14 [PMID: 35031765] (IHC-Fr, Mouse)
• Infantino R, Schiano C, Luongo L et al. MED1/BDNF/TrkB pathway is involved in thalamic hemorrhage-induced pain and depression by regulating microglia Neurobiology of disease 2022-01-04 [PMID: 34995755] (WB, Mouse)
• Chen F, Licarete E, Wu X Et al. Pharmacological inhibition of Carbonic Anhydrase IX and XII to enhance targeting of acute myeloid leukaemia cells under hypoxic conditions Journal of cellular and molecular medicine 2021-11-17 [PMID: 34791807] (IF/IHC, Human)
• Kim HS, Kang YH, Lee J Et al. Biphasic Regulation of Mitogen-Activated Protein Kinase Phosphatase 3 in Hypoxic Colon Cancer Cells Molecules and cells 2021-10-31 [PMID: 34711689] (IF/IHC, Mouse)
• Pang L, Ng KT, Liu J et al. Plasmacytoid dendritic cells recruited by HIF-1 alpha /eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma Cancer letters 2021-09-16 [PMID: 34536555] (IF/IHC, Human)
• Lin C, Lai SW, Shen CK et al. Fenofibrate inhibits hypoxia-inducible factor-1 alpha and carbonic anhydrase expression through activation of AMP-activated protein kinase/HO-1/Sirt1 pathway in glioblastoma cells Environmental toxicology 2021-09-14 [PMID: 34520103]
• Wang Y, Lyu Y, Tu K Et al. Histone citrullination by PADI4 is required for HIF-dependent transcriptional responses to hypoxia and tumor vascularization Science advances 2021-08-01 [PMID: 34452909] (IF/IHC, Human)
• Maurer GD, Tichy J, Harter PN et al. Matching Quantitative MRI Parameters with Histological Features of Treatment-Na�ve IDH Wild-Type Glioma Cancers (Basel) 2021-08-12 [PMID: 34439213] (Immunohistochemistry-Paraffin, Human)
• Brück O, Lee MH, Turkki R et Al. Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients Mod Pathol 2021-07-02 [PMID: 34215851]
• Vormittag-Nocito E, Mannan R, Wang X et al. Deciphering Intratumor Heterogeneity in Clear Cell Renal Cell Carcinoma Utilizing Clinicopathologic and Molecular Platforms Human Pathology 2022-10-01 [PMID: 34210685] (IHC-P, Human)
• Mehibel M, Xu Y, Li CG et al. Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models The Journal of clinical investigation 2021-06-01 [PMID: 34060485] (IHC-P, Human)
• Mikkelsen ML, Marcussen N, Rabjerg M Surgically Induced Ischemia has no Impact on Protein Expression Levels of HIF-1 alpha and Related Biomarkers in Renal Cell Carcinoma APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2021-05-04 [PMID: 33948984]
• Steenbrugge J, Vander Elst N, Demeyere K et al. OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer NPJ breast cancer 2021-03-17 [PMID: 33731699] (IF/IHC)
• Riechelmann H, Steinbichler TB, Sprung S et al. The Epithelial-Mesenchymal Transcription Factor Slug Predicts Survival Benefit of Up-Front Surgery in Head and Neck Cancer Cancers (Basel) 2021-02-12 [PMID: 33673269] (Immunohistochemistry-Paraffin, Human)
• Menga A, Serra M, Todisco S et al. Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages EMBO Mol Med 2020-09-04 [PMID: 32885605] (IHC-P, IF/IHC, Mouse)
• Glassman DM, Glassman D Targeting metabolic adaptations to anti-angiogenic therapy in ovarian cancer Thesis 2022-01-01 (IHC-Fr, Human)
• Anemone A, Consolino L, Conti L et al. Tumour acidosis evaluated in vivo by MRI-CEST pH imaging reveals breast cancer metastatic potential British journal of cancer 2020-12-01 [PMID: 33257841] (WB, Mouse)
  
  Details:
  Western blot analysis of TUBO cells.
• Simko V, Belvoncikova P, Csaderova L et al. PIMT Binding to C-Terminal Ala459 of CAIX Is Involved in Inside-Out Signaling Necessary for Its Catalytic Activity Int J Mol Sci 2020-11-12 [PMID: 33198416] (IF/IHC, PLA)
• Alberti D, Michelotti A, Lanfranco A et al. In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells Life (Basel) 2020-11-02 [PMID: 33159147] (IHC-P, Human)
• Fujita N, Bondoc A, Ishida J et al. Combination Treatment with Histone Deacetylase and Carbonic Anhydrase 9 Inhibitors Shows Therapeutic Potential in Experimental Diffuse Intrinsic Pontine Glioma Research Square 2022-03-10 (WB, Human)
• Huang BR, Liu YS, Lai SW et al. CAIX Regulates GBM Motility and TAM Adhesion and Polarization through EGFR/STAT3 under Hypoxic Conditions International Journal of Molecular Sciences 2020-08-14 [PMID: 32823915] (Immunohistochemistry-Paraffin, Human)
• Yelek C, Mignion L, Paquot A et al. Tumor Metabolism Is Affected by Obesity in Preclinical Models of Triple-Negative Breast Cancer Cancers (Basel)
• Gillen AE, Riemondy KA, Amani V et al. Single-Cell RNA Sequencing of Childhood Ependymoma Reveals Neoplastic Cell Subpopulations That Impact Molecular Classification and Etiology Cell Rep 2020-08-11 [PMID: 32783945]
• Ghosh P, Guo Y, Ashrafi A et al. Oxygen-enhanced optoacoustic tomography reveals the effectiveness of targeting heme and oxidative phosphorylation at normalizing tumor vascular oxygenation Cancer Res. 2020-06-16 [PMID: 32546631] (IF/IHC, Human)
• Kikuchi H, Maishi N, Annan DA et al. Chemotherapy-induced IL-8 upregulates MDR1/ABCB1 in tumor blood vessels and results in unfavorable outcome Cancer Res. 2020-06-14 [PMID: 32536602] (IHC-P, Human)
• Gong Y Enhancing the Antitumor Activity of Nk-92 Natural Killer Cells by Ectopic Expression of Sodium Hydrogen Exchanger 1 Thesis Jan 1 2022
• Hosaka K, Yang Y, Seki T et al. Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors Nat Commun 2020-07-24 [PMID: 32709869] (IHC-P, Mouse)
• MEhes G, Matolay O, Beke L et al. Carbonic Anhydrase Inhibitor Acetazolamide Enhances CHOP Treatment Response and Stimulates Effector T-Cell Infiltration in A20/BalbC Murine B-Cell Lymphoma Int J Mol Sci 2020-07-15 [PMID: 32679833]
• Lovisa S, Fletcher-Sananikone E, Sugimoto H et al. Endothelial-to-mesenchymal transition compromises vascular integrity to induce Myc-mediated metabolic reprogramming in kidney fibrosis Sci Signal 2020-06-09 [PMID: 32518142]
• Becker LM, O'Connell JT, Vo AP et al. Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer Cell Rep 2020-06-02 [PMID: 32492417] (IF, IF/IHC, Human, Mouse)
• Fu SY, Wang CC, Chen FH et al. Sunitinib Treatment-elicited Distinct Tumor Microenvironment Dramatically Compensated the Reduction of Myeloid-derived Suppressor Cells In Vivo 2020-03-11 [PMID: 32354903] (IHC-Fr, Mouse)
• Chen S, Xing C, Huang D et al. Eradication of tumor growth by delivering novel photothermal selenium-coated tellurium nanoheterojunctions Sci Adv 2020-04-01 [PMID: 32284997] (ICC/IF, Mouse)
• Kim M, Joo Jw, Lee Sj et Al. Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes Cancers (Basel) 2020-03-05 [PMID: 32150988] (IF/IHC, Human)
• Kuthi L, Somoracz a, Micsik T et al. Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma Pathol. Oncol. Res. 2020-01-18 [PMID: 31955345] (MiAr, Human)
• Brown E, Rowan C, Strowitzki MJ et al. Mucosal inflammation downregulates PHD1 expression promoting a barrier-protective HIF-1 alpha response in ulcerative colitis patients FASEB J. 2020-01-16 [PMID: 31944416] (WB, Human)
• Steenbrugge J, Vander Elst N, Demeyere K Comparative Profiling of Metastatic 4T1-vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer Front. Immunol. 2019-12-17 [PMID: 31921184] (IHC-P, Mouse)
• Abdallah MG, Buchanan-Vega JA, Lee KJ, et al. Clinicopathological Characterization of Renal Cell Carcinoma in Young Adults: a contemporary update and review of literature Histopathology 2019-12-23 [PMID: 31872452] (IF/IHC, Human)
• Elodie A. Pérès, Jérôme Toutain, Louis-Paul Paty, Didier Divoux, Méziane Ibazizène, Stéphane Guillouet, Louisa Barré, Aurélien Vidal, Michel Cherel, Mickaël Bourgeois, Myriam Bernaudin, Samuel Valable 64 Cu-ATSM/ 64 Cu-Cl 2 and their relationship to hypoxia in glioblastoma: a preclinical study EJNMMI Research 2019-12-19 [PMID: 31858290]
• Silagi ES, Novais EJ, Bisetto S et al. Lactate Efflux from Intervertebral Disc Cells is Required for Maintenance of Spine Health J. Bone Miner. Res. 2019-11-06 [PMID: 31692093] (Immunohistochemistry-Paraffin, Human)
• Xiao Y, Zhao H, Tian L et al. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma Cancer Res 2019-10-06 [PMID: 31585940] (IHC-P, Mouse, Human)
• Recondo G, Mezquita L, Facchinetti F et al. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer Clin Cancer Res 2019-10-06 [PMID: 31585938] (IHC-P, Mouse, Human)
• Kennedy JM, Wang X, Plouffe KR et al. Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series Med. Oncol. 2019-07-22 [PMID: 31332543]
• Gong Y, Shao H, Li Y et al. Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells Cancer Research Communications Aug 22 2022 (WB, Human)
• Kitson SJ, Maskell Z, Sivalingam VN et al. Optimization of Window Study Endpoints in Endometrial Cancer Front Oncol 2019-05-29 [PMID: 31214492]
• Wu Y, Terekhanova N, Caravan W et al. Chromatin accessibility shapes tumor architecture and microenvironment in clear cell renal cell carcinoma Research Square 2022-08-08 (IHC-P, Human)
  
  Details:
  Dilution used for IHC 1:350
• Matolay O, Beke L, Gyurkovics A et al. Quantitative Analysis of Carbonic Anhydrase IX Uncovers Hypoxia-Related Functional Differences in Classical Hodgkin Lymphoma Subtypes Int J Mol Sci 2019-07-15 [PMID: 31311071] (IF/IHC, Human)
• Ron A, Dean-Ben XL, Gottschalk S, Razansky, D Volumetric optoacoustic imaging unveils high-resolution patterns of acute and cyclic hypoxia in a murine model of breast cancer Cancer Res. 2019-05-16 [PMID: 31097477] (IF/IHC, Mouse)
• Reijnen, C;van Weelden, WJ;Arts, MSJP;Peters, JP;Rijken, PF;van de Vijver, K;Santacana, M;Bronsert, P;Bulten, J;Hirschfeld, M;Colas, E;Gil-Moreno, A;Reques, A;Mancebo, G;Krakstad, C;Trovik, J;Haldorsen, IS;Huvila, J;Koskas, M;Weinberger, V;Minar, L;Jandak Poor outcome in hypoxic endometrial carcinoma is related to vascular density Br. J. Cancer 2019-04-23 [PMID: 31011231] (IHC-P, Human)
• Azam, SH;Porrello, A;Harrison, EB;Leslie, PL;Liu, X;Waugh, TA;Belanger, A;Mangala, LS;Lopez-Berestein, G;Wilson, HL;McCann, JV;Kim, WY;Sood, AK;Liu, J;Dudley, AC;Pecot, CV; Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis Oncogene 2019-03-27 [PMID: 30918328] (IHC-Fr, Mouse)
• Frost J, Ciulli A, Rocha S. RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response Wellcome Open Res 2019-01-29 [PMID: 30801039] (WB, Human)
• Najjar YG, Menk AV, Sander C et al. Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma JCI Insight 2019-02-05 [PMID: 30721155] (IHC-Fr, Human)
• Schuurman, T N, Witteveen, P O Et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat 2019-05-01 [PMID: 30707336] (IF/IHC, Mouse)
  
  Details:
  Citation using the DyLight 488 format of this antibody.
• Guo H, Ci X, Ahmed M et al. ONECUT2 is a driver of neuroendocrine prostate cancer. Nat Commun 2019-01-17 [PMID: 30655535] (IHC-P, Human)
• Mehes G, Matolay O, Beke L et al. Hypoxia related carbonic anhydrase IX expression is associated with unfavourable response to first-line therapy in classical Hodgkin's lymphoma. Histopathology 2019-01-12 [PMID: 30636023] (IF/IHC, Human)
• Neal JT, Li X, Zhu J et al. Organoid Modeling of the Tumor Immune Microenvironment Cell 2018-12-13 [PMID: 30550791] (IHC-P, Human)
• Kubo H, Hanaoka K, Kuriki Y et al. Rapid detection of metastatic lymph nodes of colorectal cancer with a gamma-glutamyl transpeptidase-activatable fluorescence probe. Sci Rep 2018-12-12 [PMID: 30542087] (IHC-P, Human)
• Young JR, Coy H, Kim HJ et al. Association of the Gross Appearance of Intratumoral Vascularity at MDCT With the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma. AJR Am J Roentgenol. 2018-10-09 [PMID: 30300009] (IF/IHC, Human)
• Davis RM, Kiss B, Trivedi DR el al. Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype ACS Nano. 2018-10-23 [PMID: 30203645] (ICC/IF, Human)
• Greenhough A, Bagley C, Heesom KJ et al. Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis EMBO Mol Med 2018-08-24 [PMID: 30143543] (WB, Human)
• Burman A, Kropski JA, Calvi CL et al. Localized hypoxia links ER stress to lung fibrosis through induction of C/EBP homologous protein JCI Insight 2018-08-23 [PMID: 30135303] (IHC-P, Mouse)
• Steenbrugge J, Breyne K, Demeyere K et al. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer J. Exp. Clin. Cancer Res. 2018-08-15 [PMID: 30111338] (IHC-P, Mouse)
• Balasundaram G, Ding L, Li X et al. Noninvasive Anatomical and Functional Imaging of Orthotopic Glioblastoma Development and Therapy using Multispectral Optoacoustic Tomography Transl Oncol 2018-08-10 [PMID: 30103155] (IHC-P, Mouse)
• Perera RKS Investigating the role of the tumor microenvironment on tumor cell invasion and lymphatic dissemination Thesis (IF/IHC, Mouse)
• Lambrechts D, Wauters E, Boeckx B et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat. Med. 2018-07-09 [PMID: 29988129] (IHC-P, Human)
• Ames S, Pastorekova S, Becker HM. The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells. Oncotarget. 2018-06-15 [PMID: 29963253] (WB, Human)
• Toonen Lodewijk J A, Overzier Maurice, Evers Melvin M et al. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model. Molecular Neurodegeneration 2018-06-22 [PMID: 29929540] (WB, Mouse)
• Iwamoto H, Abe M, Yang Y et al. Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance. Cell Metab 2018-05-31 [PMID: 29861385] (ICC/IF)
• Matsumoto S, Kishimoto S, Saito K et al. Metabolic and physiologic imaging biomarkers of the tumor microenvironment predict treatment outcome with radiation or a hypoxia-activated prodrug in mice Cancer Res. 2018-05-23 [PMID: 29792309] (Immunohistochemistry-Paraffin, Human)
• Rosenberg T, Aaberg-Jessen C, Petterson SA, Kristensen BW. Heterogenic expression of stem cell markers in patient-derived glioblastoma spheroid cultures exposed to long-term hypoxia CNS Oncol 2018-04-01 [PMID: 29708435] (IF/IHC, Human)
• Dao M, Pecriaux A, Bessede T et al. BK virus-associated collecting duct carcinoma of the renal allograft in a kidney-pancreas allograft recipient Oncotarget 2018-03-13 [PMID: 29599935] (IHC-P, Human)
• Ferecatu I, Canal F, Fabbri L et al. Dysfunction in the mitochondrial Fe-S assembly machinery leads to formation of the chemoresistant truncated VDAC1 isoform without HIF-1a activation. PLoS ONE 2018-03-29 [PMID: 29596470] (WB, Human)
• Corbet C, Bastien E, Draoui N et al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. 2018-03-23 [PMID: 29572438] (IF/IHC, Human)
• Young JR, Coy H, Kim HJ et al. Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression. Abdom Radiol (NY). 2018-03-08 [PMID: 29520426] (IF/IHC)
• Dreyer-Andersen N, Almeida AS, Jensen P et al. Intermittent, low dose carbon monoxide exposure enhances survival and dopaminergic differentiation of human neural stem cells PLoS ONE 2018-01-16 [PMID: 29338033] (ICC/IF, Human)
• Boyd NH, Walker K, Fried J et al. Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in vivo. JCI Insight 2017-12-21 [PMID: 29263302] (WB, Human)
• Pinato DJ, Black JR, Trousil S et al. Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior Oncoimmunology. 2017-08-03 [PMID: 29147618] (IF/IHC, Human)
• He L, Zhao C, Li Y et al. Antiangiogenic effects of recombinant human endostatin in lung cancers. Mol Med Rep. 2017-01-01 [PMID: 29115591] (Mouse)
• W Zhou, C Chen, Y Shi, Q Wu, RC Gimple, X Fang, Z Huang, K Zhai, SQ Ke, YF Ping, H Feng, JN Rich, JS Yu, S Bao, XW Bian Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy Cell Stem Cell, 2017-11-02;21(5):591-603.e4. 2017-11-02 [PMID: 29100012] (Immunohistochemistry-Paraffin, Human)
• Ou D, Garberis I, Adam J et al. Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy. Radiother Oncol 2018-01-01 [PMID: 29079308] (IF/IHC)
• Nakamura M, Zhang Y, Yang Y et al. Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production. Proc. Natl. Acad. Sci. U.S.A. 2017-10-23 [PMID: 29078273] (Mouse)
• Wang D, Berglund AE, Kenchappa RS et al. BIRC3 is a biomarker of mesenchymal habitat of glioblastoma, and a mediator of survival adaptation in hypoxia-driven glioblastoma habitats Sci Rep 2017-08-24 [PMID: 28839258] (WB, Mouse)
• Bucau M, Laurent-Bellue A, Pote N et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation Neuroendocrinology 2017-08-11 [PMID: 28803235] (Human)
• Dong Y, Manley B J et al. Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. Eur Urol Focus 2016-08-25 [PMID: 28753786] (IF/IHC, Mouse)
• Klameth L, Rath B, Hochmaier M et al. Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance Sci Rep 2017-07-13 [PMID: 28706293] (IHC-P, Human)
• Zhang Y, Sun M, Huang G et al. Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 2017-06-27 [PMID: 28607065]
• Takenaka M, Suzuki N, Mori M et al. Iron regulatory protein 2 in ovarian endometrial cysts. Biochem. Biophys. Res. Commun. 2017-04-24 [PMID: 28450115]
• Bousquet G, El Bouchtaoui M, Sophie T et al. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer. Oncotarget. 2017-05-23 [PMID: 28445132] (ICC/IF, Human)
• Tudisco Laura, Orlandi Augusto, Tarallo Valeria et al. Hypoxia activates placental growth factor expression in lymphatic endothelial cells. Oncotarget 2017-01-01 [PMID: 28427198] (IF/IHC, Mouse)
• Lee DH, Cheul Oh S, Giles AJ et al. Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1 alpha in human glioma stem cells Oncotarget 2017-06-20 [PMID: 28410215] (IF/IHC, Mouse)
• Himmels P, Paredes I, Adler H et al. Motor neurons control blood vessel patterning in the developing spinal cord. Nat Commun. 2017-03-06 [PMID: 28262664] (IHC-Fr, Mouse)
• Fraga A, Ribeiro R, Coelho A et al. Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer. BMC Urol 2017-01-31 [PMID: 28143503] (Human)
• Bulusu V, Tumanov S, Michalopoulou E et al. Acetate Recapturing by Nuclear Acetyl-CoA Synthetase 2 Prevents Loss of Histone Acetylation during Oxygen and Serum Limitation Cell Rep 2017-01-17 [PMID: 28099844] (IF/IHC, Human)
• Tsuji T, Kurokawa Y, Chiche J et al. Dissecting the process of activation of cancer-promoting zinc-requiring ectoenzymes by zinc metalation mediated by ZnT transporters J. Biol. Chem 2016-12-27 [PMID: 28028180] (WB)
• Oh ET, Kim JW, Kim JM et al. NQO1 inhibits proteasome-mediated degradation of HIF-1a. Nat Commun. 2016-12-14 [PMID: 27966538] (IF/IHC, Mouse)
• Frost J, Galdeano C, Soares P et al. Potent and selective chemical probe of hypoxic signalling downstream of HIF-alpha hydroxylation via VHL inhibition. Nat Commun. 2016-11-04 [PMID: 27811928] (WB)
• Cauchy F, Mebarki M, Leporq B et al. Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. Clin. Sci. 2016-11-01 [PMID: 27803295]
• Eikrem OS, Strauss P, Beisland C et al. Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing. Scand J Urol 2016-12-01 [PMID: 27739342] (IF/IHC, Human)
• Huang Y, Lichtenberger LM, Taylor M et al. Anti-tumor and Anti-angiogenic Effects of Aspirin-PC in Ovarian Cancer Mol. Cancer Ther. 2016-09-16 [PMID: 27638860] (IF/IHC, Human)
• Knudsen ES, Balaji U, Freinkman E et al. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget. 2016-11-29 [PMID: 27623078] (Immunohistochemistry-Paraffin, Human)
• Kim En, Kim Gh, Kim J et al. A Pyloric Gland-Phenotype Ovarian Mucinous Tumor Resembling Lobular Endocervical Glandular Hyperplasia in a Patient with Peutz-Jeghers Syndrome. J Pathol Transl Med 2016-08-22 [PMID: 27550049] (IHC-P)
• van Kuijk SJ, Gieling RG, Niemans R et al. The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy. PLoS ONE. 2016-08-12 [PMID: 27513947] (IF/IHC, Human)
• Hirakawa T, Yashiro M, Doi Y et al. Pancreatic Fibroblasts Stimulate the Motility of Pancreatic Cancer Cells through IGF1/IGF1R Signaling under Hypoxia. PLoS ONE. 2016-08-04 [PMID: 27487118] (IF/IHC, Human)
• Yoon C, Chang KK, Lee JH et al. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1a inhibition, and hypoxia-activated chemotherapy Oncotarget 2016-07-12 [PMID: 27374091] (Mouse)
• Leek R, Grimes DR, Harris AL, McIntyre A. Methods: Using Three-Dimensional Culture (Spheroids) as an In Vitro Model of Tumour Hypoxia. Adv. Exp. Med. Biol. 2016-06-21 [PMID: 27325267] (IF/IHC, Mouse, Human)
• He H, Yang Y, Xiang Z et al. A Sensitive IHC Method for Monitoring Autophagy-Specific Markers in Human Tumor Xenografts. J Biomark. 2016-06-01 [PMID: 27247826] (IHC-P, Human)
• Hecht JL, Zsengeller ZK, Spiel M, Karumanchi SA. Revisiting decidual vasculopathy. Placenta. 2016-04-08 [PMID: 27238712] (IHC-P, Human)
• Xu W, Ghosh S, Comhair SA et al. Increased mitochondrial arginine metabolism supports bioenergetics in asthma. J. Clin. Invest. 2016-05-23 [PMID: 27214549] (IHC-P, Mouse)
• Badar T, Handisides DR, Benito JM et al. A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia. Am. J. Hematol. 2016-05-11 [PMID: 27169385] (IHC-P, Human)
• Faes S, Planche A, Uldry E et al. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors. Oncotarget. 2016-06-14 [PMID: 27153561] (IF/IHC, Mouse)
• Ono M, Yamada K, Bensaddek D et al. Enhanced snoMEN Vectors Facilitate Establishment of GFP-HIF-1alpha Protein Replacement Human Cell Lines. PLoS ONE. 2016-04-30 [PMID: 27128805] (WB, Human)
• Eikrem O, Beisland C, Hjelle K et al. Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development PLoS ONE 2016-02-23 [PMID: 26901863] (IHC-P, Human)
• Radoul M, Chaumeil MM, Eriksson P et al. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. Mol. Cancer Ther. 2016-05-01 [PMID: 26883274] (IF/IHC, Mouse)
• Scholz A, Harter PN, Cremer S et al. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma. EMBO Mol Med. 2016-01-05 [PMID: 26666269] (IHC-P, Human)
• Ortmann B, Bensaddek D, Carvalhal S et al. CDK-dependent phosphorylation of PHD1 on serine 130 alters its substrate preference in cells J Cell Sci. 2015-12-31 [PMID: 26644182] (WB, Human)
• Mitsuhashi A, Goto H, Saijo A et al. Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab. Nat Commun. 2015-12-04 [PMID: 26635184] (IHC-Fr, Mouse)
• Andre H, Tunik S, Aronsson M, Kvanta A. Hypoxia-Inducible Factor-1alpha Is Associated With Sprouting Angiogenesis in the Murine Laser-Induced Choroidal Neovascularization Model. ARVO Journals. 2015-10-01 [PMID: 26501235] (ICC/IF, Mouse)
• Klier M, Jamali S, Ames S et al. Catalytic activity of human carbonic anhydrase isoform IX is displayed both extra- and intracellularly. FEBS J 2016-01-01 [PMID: 26470855]
• Islam SS, Mokhtari RB, Akbari P et al. Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN). Target Oncol 2015-10-10 [PMID: 26453055]
• Kinoshita H, Yashiro M, Fukuoka T et al. Diffuse-type Gastric Cancer Cells Switch Their Driver Pathways from FGFR2 Signaling to SDF1/CXCR4 Axis in Hypoxic Tumor Microenvironments. Carcinogenesis 2015-09-18 [PMID: 26385890] (IHC-P, Mouse)
• Jamali S, Klier M, Ames S et al. Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci Rep 2015-09-04 [PMID: 26337752] (WB, ICC/IF, Human)
• Baine MK, Turcu G, Zito CR et al. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget 2015-09-22 [PMID: 26317902]
• Song CW, Lee YJ, Griffin RJ et al. Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery. Int J Radiat Oncol Biol Phys 2015-09-01 [PMID: 26279032]
• Ward C, Meehan J, Mullen P et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models Oncotarget 2015-07-04 [PMID: 26259239]
• Kasashima H, Yashiro M, Kinoshita H et al. Lysyl oxidase is associated with the epithelial-mesenchymal transition of gastric cancer cells in hypoxia. Gastric Cancer 2016-04-01 [PMID: 26100130]
• Yoon C, Lee HJ, Park DJ et al. Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas. Br. J. Cancer. 2015-05-26 [PMID: 26010414] (ICC/IF, IHC-P, Human)
• Brossa Alessia, Grange Cristina, Mancuso Letizia et al. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. Oncotarget 2015-01-01 [PMID: 25948774] (IF/IHC, ICC/IF, Mouse)
• Dulloo I, Phang BH, Othman R et al. Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome. Nat. Cell Biol. 2015-04-01 [PMID: 25774835] (IHC-P, Human)
• Cotroneo E, Ashek A, Wang L et al. Iron Homeostasis and Pulmonary Hypertension: Iron Deficiency Leads to Pulmonary Vascular Remodeling in the Rat. Circ. Res. 2015-03-12 [PMID: 25767292] (IF/IHC, Rat)
• Kang HJ, Kim IH, Sung CO et al. Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma Virchows Arch. 2015-01-11 [PMID: 25577552] (IHC-P, Human)
  
  Details:
  Carbonic Anhydrase IX/CA9 antibody used at 1:1000 dilution for IHC-P staining on formalin-fixed, paraffin-embedded tissue sections/TMAs created from surgically resected hepatocellular carcinoma/HCC and adjacent non-neoplastic liver tissue - 32 minutes of heat-induced epitope retrieval with Cell Conditioning 1 /CC1 buffer, 16 minutes of primary antibody incubation on Ventana's autoimmunostainer/Bench Mark XT automatic immunostaining device, staining development with Ventana's OptiView DAB IHC Detection Kit. Fig 2a-f documents the staining images showing weak, moderate and strong membranous expression levels of carbonic anhydrase 9 protein and the overall data in this study establishes CA9 protein as a poor prognostic factor in resectable HCC patients.
• Mudie S, Bandarra D, Batie M et al. PITX1, a specificity determinant in the HIF-1alpha-mediated transcriptional response to hypoxia. Cell Cycle 2014-01-01 [PMID: 25558831] (WB)
• Lee H, Yoon C, Park DJ et al. Inhibition of Vascular Endothelial Growth Factor A and Hypoxia-Inducible Factor 1alpha Maximizes the Effects of Radiation in Sarcoma Mouse Models Through Destruction of Tumor Vasculature. Int. J. Radiat. Oncol. Biol. Phys. 2014-12-24 [PMID: 25544668]
• Janmohamed SR, Brinkhuizen T, den Hollander JC et al. Support for the hypoxia theory in the pathogenesis of infantile haemangioma. Clin. Exp. Dermatol. 2014-12-16 [PMID: 25511669] (IHC-P, Human)
• Lin XY, Zhang H, Tang N et al. Expression and diagnostic implications of carbonic anhydrase IX in several tumours with predominantly clear cell morphology. Histopathology. 2014-11-27 [PMID: 25431204] (IHC-P, Human)
  
  Details:
  Carbonic Anhydrase IX/CA9 antibody used for IHC-P on sections of clear cell renal cell carcinoma (ccRCC; primary and metastatic) and several other type of tumors with predominantly clear cell morphology - tissues previously fixed in 10% neutral buffered formalin and embedded in paraffin, 4um sections, routine IHC-P processing with streptavidin-peroxidase detection system. ccRCC, and breast / pulmonary/hepatic clear cell carcinoma, urothelial carcinoma with clear cell change, clear cell meningioma/ependymoma, haemangioblastoma, and clear cell hidradenoma showed expression of CAIX. See full text for staining images and the expression levels.
• Gellert LL, Mehra R, Chen YB et al. The diagnostic accuracy of percutaneous renal needle core biopsy and its potential impact on the clinical management of renal cortical neoplasms. Arch. Pathol. Lab. Med. 2014-12-01 [PMID: 25427045] (IHC-P, Human)
  
  Details:
  Carbonic Anhydrase IX/CA9 antibody used for IHC-P on sections of human renal biopsies having sarcomatoid area with focal necrosis and clear cell renal cell carcinoma (Figure 3.).
• Santos Cd, Tijeras-Raballand A, Serova M et al. Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma. Br. J. Cancer. 2014-11-25 [PMID: 25422908] (IHC-P, Human)
• Burgi S, Seuwen A, Keist R et al. In Vivo Imaging of Hypoxia-Inducible Factor Regulation in a Subcutaneous and Orthotopic GL261 Glioma Tumor Model Using a Reporter Gene Assay. Mol Imaging. 2014-09-01 [PMID: 25248521] (Immunohistochemistry-Paraffin, Human)
• Meijer Tineke W H, Bussink Johan, Zatovicova Miriam et al. Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model. PloS One 2014-01-01 [PMID: 25225880] (IF/IHC, Mouse)
• Hwa JS, Kwon OJ, Park JJ et al. The prognostic value of immunohistochemical markers for oral tongue squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2014-08-29 [PMID: 25169079]
• Chen LQ, Howison CM, Spier C et al. Assessment of carbonic anhydrase IX expression and extracellular pH in B-cell lymphoma cell line models. Leuk. Lymphoma. 2014-08-17 [PMID: 25130478]
• Motzer Robert J, Hutson Thomas E, Hudes Gary R et al. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014-08-07 [PMID: 25100134] (IHC-P, Human)
• Guo Jianying, Shinriki Satoru, Su Yu et al. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy. Oncotarget 2014-01-01 [PMID: 25071012] (IF/IHC, Human)
• Sadlecki P, Bodnar M, Grabiec M. The Role of Hypoxia-Inducible Factor-1a, Glucose Transporter-1,(GLUT-1) and Carbon Anhydrase IX in Endometrial Cancer Patients. BioMed Research International 2014-03-12 [PMID: 24745019] (IHC-P, Human)
• Heijmen L, Voert EGW, Punt CJA. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging 2014-05-01 [PMID: 24700751] (IHC-Fr, Human)
  
  Details:
  Using the Biotin conjugated version of NB100-417, catalog number NB100-417B.
• Kwon OJ, Park JJ, Ko GH et al. HIF-1a and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma. Head Neck 2014-02-12 [PMID: 24677746] (IHC-P, Human)
• Chen X, Iliopoulos D, Zhang Q et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1a pathway. Nature 2014-04-03 [PMID: 24670641] (IHC-P, Human)
• Morifuji Yoshihiro, Onishi Hideya, Iwasaki Hironori et al. Reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic cancer through the Hedgehog signaling. Cancer Sci. 2014-02-11 [PMID: 24397700]
• Polanski Radoslaw, Hodgkinson Cassandra L, Fusi Alberto et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014-02-15 [PMID: 24277449] (IF/IHC)
• Pinato DJ, Tan TM, Toussi ST et al. An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes. Br J Cancer. 2013-11-14 [PMID: 24231952] (IHC-P, Human)
• Chaudary N, Pintilie M, Schwock J et al. Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). Cancers (Basel) 2012-01-01 [PMID: 24213469] (IF/IHC)
• Zhang M, Boughton P, Rose B et al. The Use of Porous Scaffold as a Tumor Model. Int J Biomater. 2013-01-01 [PMID: 24101930] (IF/IHC, Human)
• Wen YA, Stevens PD, Gasser ML et al. Downregulation of PHLPP Expression Contributes to Hypoxia-Induced Resistance to Chemotherapy in Colon Cancer Cells. Mol Cell Biol. 2013-11-01 [PMID: 24061475] (WB, Human)
• El-Heliebi A, Kroneis T, Zohrer E et al. Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer?. J Transl Med. 2013-09-17 [PMID: 24044779] (ICC/IF, Human)
• Fahling M, Mathia S, Paliege A et al. Tubular von Hippel-Lindau Knockout Protects against Rhabdomyolysis-Induced AKI. J Am Soc Nephrol. 2013-08-22 [PMID: 23970125]
• Bussolati B, Lauritano C, Moggio A et al. Renal CD133+/CD73+ Progenitors Produce Erythropoietin under Hypoxia and Prolyl Hydroxylase Inhibition. J Am Soc Nephrol 2013-05-09 [PMID: 23661806]
• Carbonell WS, Delay M, Jahangiri A et al. beta1 Integrin Targeting Potentiates Antiangiogenic Therapy and Inhibits the Growth of Bevacizumab-Resistant Glioblastoma. Cancer Res 2013-05-15 [PMID: 23644530] (IHC-P, ICC/IF, Human)
• Wasser, Y, Y The Role of Dlk1 in the Gene Regulatory Network Underlying Motor Neuron Diversification Thesis 2022-01-01 (WB, Mouse)
• Cioffi S, Martucciello S, Fulcoli FG et al. Tbx1 regulates brain vascularization. Hum Mol Genet. 2013-09-07 [PMID: 23945394] (ICC/IF, IHC-Fr, Mouse)
• Kumar S, Mokhtari RB, Oliveira ID et al. Tumor Dynamics in Response to Antiangiogenic Therapy with Oral Metronomic Topotecan and Pazopanib in Neuroblastoma Xenografts. Transl Oncol 2013-08-01 [PMID: 23908692] (IF/IHC, Human)
• Dubois L, Peeters SG, van Kuijk SJ et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs. Radiother Oncol 2013-07-09 [PMID: 23849171] (IHC-Fr, Mouse)
• Campanile C, Arlt MJ, Kramer SD et al. Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models. J Nucl Med 2013-06-25 [PMID: 23801674]
• Cho SY, Lee HJ, Lee HJ et al. Activation of AMP-Activated Protein Kinase alpha and Extracelluar Signal-Regulated Kinase Mediates CB-PIC-Induced Apoptosis in Hypoxic SW620 Colorectal Cancer Cells Evid Based Complement Alternat Med 2013-01-01 [PMID: 23589723] (IHC-P, Human)
• Aarntzen EH, Srinivas M, Bonetto F et al. Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clin Cancer Res 2013-03-15 [PMID: 23382117] (IF/IHC, Human)
• Zhang Q, Bai X, Chen W et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013-01-27 [PMID: 23358852] (WB, Human)
• Heijmen L, Punt CJ, Ter Voert EG et al. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Invest New Drugs 2013-01-17 [PMID: 23325291] (ICC/IF, IF/IHC, Mouse)
  
  Details:
  Using the Biotin conjugated version of NB100-417, catalog number NB100-417B.
• Pinato DJ, Ramachandran R, Toussi ST et al. Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations Br J Cancer 2012-12-20 [PMID: 23257898] (IF/IHC, Human)
• Delhaas T, Van der Meer SF, Schaart G et al. Steep Increase in Myonuclear Domain Size During Infancy Anat Rec (Hoboken) 2012-12-04 [PMID: 23213045] (IF/IHC, ICC/IF, Human)
• Proescholdt MA, Merrill MJ, Stoerr EM et al. Function of carbonic anhydrase IX in glioblastoma multiforme Neuro Oncol 2012-11-01 [PMID: 23074198] (IF/IHC, WB, Human)
• Currie MJ, Beardsley BE, Harris GC et al. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity Hum Pathol 2012-10-01 [PMID: 23036368] (IF/IHC, Human)
• Piao Y, Liang J, Holmes L et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype Neuro Oncol 2012-09-10 [PMID: 22965162] (IF/IHC, Human, Mouse)
• Muriel Lopez C, Esteban E, Berros JP et al. Prognostic Factors in Patients With Advanced Renal Cell Carcinoma Clin Genitourin Cancer 2012-09-06 [PMID: 22959659] (IF/IHC, Human)
• Brouillet S, Murthi P, Hoffmann P et al. EG-VEGF controls placental growth and survival in normal and pathological pregnancies: case of fetal growth restriction (FGR) Cell Mol Life Sci 2012-09-02 [PMID: 22941044] (IF/IHC, Human)
• Engler JR, Robinson AE, Smirnov I et al. Increased microglia/macrophage gene expression in a subset of adult and pediatric astrocytomas PLoS One 2012-01-01 [PMID: 22937035] (IF/IHC, Human)
• Yin S, Kaluz S, Devi NS et al. Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1alpha Interaction with Cofactors p300/CBP Clin Cancer Res 2012-12-15 [PMID: 22923450] (WB, Human)
• Park I, Hu S, Bok R et al. Evaluation of heterogeneous metabolic profile in an orthotopic Human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med 2013-07-01 [PMID: 22851374] (IHC-P, Rat)
• Fromy B, Lingueglia E, Sigaudo-Roussel D et al. Asic3 is a neuronal mechanosensor for pressure-induced vasodilation that protects against pressure ulcers Nat Med 2012-07-29 [PMID: 22842475] (IF/IHC, Mouse)
• Eguchi D, Ikenaga N, Ohuchida K et al. Hypoxia enhances the interaction between pancreatic stellate cells and cancer cells via increased secretion of connective tissue growth factor J Surg Res 2012-07-06 [PMID: 22795353] (IF/IHC, Human)
• Albert S, Hourseau M, Halimi C et al. Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncol 2012-12-01 [PMID: 22776129]
• Muriel Lopez C, Esteban E, Astudillo A, Pardo P, Berros JP, Izquierdo M, Crespo G, Fonseca PJ, Sanmamed M, Martinez-Camblor P. Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs. 2012-05-27 [PMID: 22644070] (IF/IHC, Human)
• Pellegrini L, Pucci B, Villanova L et al. SIRT3 protects from hypoxia and staurosporine-mediated cell death by maintaining mitochondrial membrane potential and intracellular pH Cell Death Differ [PMID: 22595756] (WB, Human)
  
  Details:
  Used the IHC-Prediluted form of this antibody.
• Weber DC, Tille JC, Combescure C et al. The prognostic value of expression of HIF1alpha, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy Radiat Oncol 2012-04-30 [PMID: 22546016] (IF/IHC, Human)
• Onishi H, Morifuji Y, Kai M, Suyama K, Iwasaki H, Katano M. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci. 2012-04-06 [PMID: 22486854] (IF/IHC, ICC/IF, Mouse)
• Speisky D, Duces A, Bieche I et al. Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. Clin Cancer Res;18(10):2838-2849. 2012-05-15 [PMID: 22461457] (IF/IHC, Human)
• Matsumura Y, Ishii G, Aokage K, Kuwata T, Hishida T, Yoshida J, Nishimura M, Nagai K, Ochiai A. Morphophenotypic characteristics of intralymphatic cancer and stromal cells susceptible to lymphogenic metastasis. Cancer Sci. 2012-03-16 [PMID: 22429811] (IF/IHC, Human)
• Wang Y, Roche O, Xu C et al. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1 Proc Natl Acad Sci U S A 2012-03-12 [PMID: 22411794] (WB, EMSA, Human)
• Lim CS, Kiriakidis S, Paleolog EM, Davies AH. Increased activation of the hypoxia-inducible factor pathway in varicose veins. J Vasc Surg;55(5):1427-1439e1. 2012-05-01 [PMID: 22277691] (WB, Human)
• Deschamps L, Bacha D, Rebours V, Mebarki M, Bretagnol F, Panis Y, Bedossa P, Ruszniewski P, Couvelard A. The Expression of the Hypoxia Markers CA9 and CXCR4 Is Correlated with Survival in Patients with Neuroendocrine Tumours of the Ileum. Neuroendocrinology. 2011-11-29 [PMID: 22133596] (IF/IHC, Human)
• Jung JH, Kim HJ, Yeom J, Yoo C, Shin J, Yoo J, Kang CS, Lee C. Lowered expression of galectin-2 is associated with lymph node metastasis in gastric cancer. J Gastroenterol;47(1):37-48. 2012-01-01 [PMID: 22015694] (WB, Human)
• Guise CP, Abbattista MR, Tipparaju SR et al. Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia. Mol Pharmacol. 2011-10-07 [PMID: 21984255]
• Ogino T, Onishi H, Suzuki H et al. Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions. Cancer Immunology, Immunotherapy: CII. 2011-09-20 [PMID: 21932134]
• Melvin A, Mudie S, Rocha S. The chromatin remodeler ISWI regulates the cellular response to hypoxia: role of FIH. Mol Biol Cell 2011-11-01 [PMID: 21900490] (Human)
• Benito J, Shi Y, Szymanska B et al. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS ONE. 2011-01-01 [PMID: 21853076]
• Garcia-Parra R, Wood D, Shah RB et al. Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by (18)F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging. 2011-07-16 [PMID: 21833840] (IHC-P, Human)
• Chaumeil MM, Ozawa T, Park I et al. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. NeuroImage. [PMID: 21807103] (IHC-P, Rat)
• Chamboredon S, Ciais D, Desroches-Castan A et al. Hypoxia-inducible Factor-1{alpha} mRNA: a new target for destabilization by tristetraprolin in endothelial cells. Mol Biol Cell. 2011-07-20 [PMID: 21775632] (WB, Human)
• Al-Ahmadie HA, Alden D, Fine SW et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am. J. Surg. Pathol. 2011-07-01 [PMID: 21677535] (IF/IHC, Human)
• Mackenzie KA, Miller AP, Hock BD, Gardner J, Simcock JW, Roake JA, Dachs GU, Robinson BA, Currie MJ. Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. Histopathology;58(6):875-85. 2011-05-01 [PMID: 21585427] (IF/IHC, Human)
• Nelson MP, Christmann BS, Werner JL et al. IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina. J Immunol 2011-02-15 [PMID: 21220696] (Chemotaxis)
• Dachs Gabi U, Kano Maiko, Volkova Ekaterina et al. A profile of prognostic and molecular factors in European and Maori breast cancer patients. BMC Cancer 2010-01-01 [PMID: 20932344] (IF/IHC, Human)
• Li Y, Wang H, Tu C et al. Role of hypoxia and EGF on expression, activity, localization and phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast cancer cells. Biochim Biophys Acta. 2010-10-01 [PMID: 20920536] (WB, Human)
• Lapinski JE, Chen L, Zhou M. Distinguishing clear cell renal cell carcinoma, retroperitoneal paraganglioma, and adrenal cortical lesions on limited biopsy material: utility of immunohistochemical markers. Appl Immunohistochem Mol Morphol;18(5):414-21. 2010-10-01 [PMID: 20861762] (IF/IHC, Human)
• Newton IP, Kenneth NS, Appleton PL et al. Adenomatous polyposis coli and hypoxia-inducible factor-1{alpha} have an antagonistic connection. Mol Biol Cell 2010-11-01 [PMID: 20844082] (Chemotaxis)
• Pistollato F, Rampazzo E, Persano L et al. Interaction of hypoxia-inducible factor-1a and Notch signaling regulates medulloblastoma precursor proliferation and fate. Stem Cells 2010-11-01 [PMID: 20827750] (IHC-P, Human)
• Kato Y, Yashiro M, Noda S et al. Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion 2010-01-01 [PMID: 20588040] (IF/IHC, Human)
• O'Toole D, Couvelard A, Rebours V et al. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer 2010-12-01 [PMID: 20570957] (IF/IHC, Human)
• Stillebroer AB, Mulders PF, Boerman OC et al. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 2010-07-01 [PMID: 20359812]
• Pistollato F, Abbadi S, Rampazzo E et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells 2010-05-01 [PMID: 20309962] (IHC-P, Human)
• Park I, Larson PE, Zierhut ML et al. Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol 2010-02-01 [PMID: 20150380] (IF/IHC)
• Magnusson P, Jauhiainen S, Onyeogaziri F et al. Proteomics on Human Cerebral Cavernous Malformations Reveals Novel Biomarkers for the Disease Pathology SSRN 2023-11-06
• Arvidsson Y, Bergstrom A, Arvidsson L et al. Hypoxia stimulates CXCR4 signalling in ileal carcinoids. Endocr Relat Cancer 2010-06-01 [PMID: 20071457] (IF/IHC, Human)
• Zhou GX, Ireland J, Rayman P et al. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology 2010-02-01 [PMID: 19963243] (ELISA, Human)
• Narita T, Yin S, Gelin CF et al. Identification of a Novel Small Molecule HIF-1{alpha} Translation Inhibitor. Clin Cancer Res 9;15(19):6128-6136. [PMID: 19789328] (WB, Human)
• Hong YS, Cho HJ, Kim SY et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009-01-01 [PMID: 19619339] (IF/IHC, Human)
• Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of Glioblastoma Resistance Invasion during Antivascular Endothelial Growth Factor Therapy. Clin Cancer Res:1078-0432.CCR-1009-0575. 2009-01-01 [PMID: 19567589] (IHC-P, Human)
• Loinard C, Ginouves A, Vilar J et al. Inhibition of prolyl hydroxylase domain proteins promotes therapeutic revascularization. Circulation 2009-07-01 [PMID: 19546390] (WB, Mouse, Human)
• Li Y, Wang H, Oosterwijk E et al. Antibody-specific detection of CAIX in breast and prostate cancers. Biochem Biophys Res Commun 2009-08-28 [PMID: 19538935] (IHC-P, Human)
• Chen J, Kobayashi M, Darmanin S et al. Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation. Am J Pathol;175(1):400-411. 2009-01-01 [PMID: 19528349] (IHC-P, Mouse)
• Di Napoli A, Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 2009-05-15 [PMID: 19402057] (Human)
• Banuelos CA, Banath JP, Kim J-Y et al. {gamma}H2AX Expression in Tumors Exposed to Cisplatin Fractionated Irradiation. Clin Cancer Res;15(10):3344-3353. 2009-01-01 [PMID: 19401347] (IHC-P, Human)
• Li Ying, Wang Hai, Oosterwijk Egbert et al. Expression and activity of carbonic anhydrase IX is associated with metabolic dysfunction in MDA-MB-231 breast cancer cells. Cancer Investigation 2009-01-01 [PMID: 19367501] (WB, Human)
• Nakao M, Ishii G, Nagai K et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009-06-15 [PMID: 19365853] (WB, Human)
• Dumais J. Plant morphogenesis: a role for mechanical signals. Curr Biol 2009-03-10 [PMID: 19278636] (IF/IHC, Plant)
• Bachmann IM, Ladstein RG, Straume O et al. Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 2008-01-01 [PMID: 19061491] (IF/IHC, Human)
• Skapa P, Hyrsl L, Zavada J et al. Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component. J Clin Oncol 2008-08-01 [PMID: 18669473] (Human)
• Sakata K, Someya M, Nagakura H et al. Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers. Jpn J Clin Oncol;38(6):402-7. 2008-06-01 [PMID: 18573850] (IHC-P, Human)
• Al-Ahmadie HA, Alden D, Qin LX et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 2008-03-01 [PMID: 18300814] (IF/IHC, Human)
• Baia GS, Dinca EB, Ozawa T et al. An orthotopic skull base model of malignant meningioma. Brain Pathol 2008-04-01 [PMID: 18093250] (IHC-P, Mouse)
• Gauter-Fleckenstein B, Fleckenstein K, Owzar K et al. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med 2008-03-15 [PMID: 18082148] (IHC-P, Rat)
• Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res;11(10):3714-21. 2005-05-15 [PMID: 15897568] (IF/IHC, Human)
• DeJohn C Noninvasive Imaging of the Immune-Vascular Crosstalk in Head and Neck Cancer Thesis 2023-01-01
• Yoo, H et al. Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. Clin Cancer Res;13 (1):68-75. 2007-01-01 [PMID: 17200340] (IHC-P, Human)
• Lee MH The immunological profile of renal cell carcinoma patients Thesis 2023-01-01 (IHC, Human)
• Aubin RG Understanding the Cellular and Gene-Regulatory Mechanisms Underlying the Mesenchymal Transition of Ependymoma Tumor Cells Using Omics Approaches Thesis 2023-01-01
• Kaidi A, Moorghen M, Williams AC et al. Is the downregulation of EphB2 receptor expression during colorectal tumorigenesis due to hypoxia?. Gut 56(11):1637-8. 2007-11-01 [PMID: 17938437] (IHC-P, Human)
• Westbury CB, Pearson A, Nerurkar A et al. Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. Br J Radiol;80(959):934-8. 2007-11-01 [PMID: 17908818] (IHC-P, Human)
• Chen L, Chen L, Huang J et al. Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma: a morphometrical study of treatment effect. Int J Clin Exp Pathol. 2016-01-01 (IHC-P, Human)
• Van den Eynden GG, Van der Auwera I, Van Laere SJ et al. Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer;93(10):1128-36. 2005-11-14 [PMID: 16251878] (IHC-P, Human)
• Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol;26(2):271-8. 2008-01-10 [PMID: 1818266] (IHC-P, Human)

Reviews for Carbonic Anhydrase IX/CA9 Antibody (NB100-417) (7)

Average Rating: 4.4

(Based on 7 reviews)

We have 7 reviews tested in 2 species: Human, Mouse.

reviewed by: Daiana Drehmer WB Human 05/31/2022

Summary

• Application: Western Blot
• Sample Tested: breast cancer MCF7 cells,Cancer Cell lysate
• Species: Human
• Lot: AQ-2

reviewed by: Lydia Taverne IHC-P Human 01/27/2020

Summary

• Application: Immunohistochemistry-Paraffin
• Sample Tested: Stomach tissue
• Species: Human
• Lot: AK

Comments

• Comments: Used citrate pH 6 antigen retrieval buffer to prepare the tissue. Applied the antibody at 1:250 concentration and detected with an AF546 labelled goat-anti-rabbit secondary antibody. Nuclei detected with DAPI.

reviewed by: Verified Customer Immunofluorescence in frozen tissue/Immunofluorescence in vibratome cut tissue Mouse 01/23/2019

Summary

• Application: Other
• Sample Tested: P15 Mouse Brain
• Species: Mouse
• Lot: AB1

Comments

• Comments: PFA fixed P15 mouse brains were cut 80µm using a vibratome and the sections were blocked in NGS (10%) in PBST (0.3% TritonX100) for 2 hrs at RT and incubated in primary antibody prepared in blocking buffer at 4 degrees overnight. after 3 washes in PBS (10 min each), the sections were stained in alexa-fluor conjugated secondary ab for 2 hrs at RT.

reviewed by: Verified Customer IHC-P Mouse 10/25/2017

Summary

• Application: Immunohistochemistry-Paraffin
• Sample Tested: IHC on parrafin sections (mouse)
• Species: Mouse
• Lot: AD-1

reviewed by: rajesha rupaimoole WB Human 12/10/2014

Summary

• Application: Western Blot
• Sample Tested: A2780 ovarian cancer cells
• Species: Human

reviewed by: Xiuquan Luo WB Human 07/21/2014

Summary

• Application: Western Blot
• Sample Tested: 20 ug whole cell lysate
• Species: Human

reviewed by: Sonia Rocha ICC Human 12/21/2011

Summary

• Application: Immunocytochemistry
• Sample Tested: Human cells
• Species: Human

FAQs for Carbonic Anhydrase IX/CA9 Antibody (NB100-417). (Showing 1 - 9 of 9 FAQs).

1. How many units do we need to purchase in order to stain 150 formalin fixed, paraffin embedded kidney biopsies? It depends on the amount used per slide, so could you please confirm how much antibody do you use per slide in IHC-P? Also, is the ab compatible with ENVISION FLEX+, HIGH pH, FOR AS?
   • Unfortunately there is no number that I can provide to you as it is impossible to know for sure how many slides you will be able to stain with a vial. This will depend on your experimental conditions, your samples and how highly expressed the protein is, and what dilution you end up choosing. This antibody is recommended to be used at a 1:1000 dilution for IHC staining as this has worked well for our lab. You should order a single vial and test to determine what amount will be best for your assay rather than order too much or too little without first working with the antibody. As for your second question, that is not something that our lab has tested with so I am unsure if it is compatible or not. It has a fairly normal range pH in the buffer (7-8) so most likely the functions best around that range and not at a high pH.
2. Could you please let me know the immunogen peptide location for this Ab?
   • The immunogen used to create this antibody was made to a cytoplasmic area of the protein.
3. I'm going to use your CA-9 Antibody for paraffin-Immunohistochemistry. Do I have to do any special pretreatments?
   • We recommend antigen retrieval to ensure the epitope is not masked, and we also recommend that you add a permeablizing agent to access the epitope in the nucleus. A protocol specific for this product can be found under Product PDFs, labelled as "IHC Protocol". 
4. We dilute our antibodies in 5% milk TBS-Tween and usually freeze-thaw them multiple times. Is this possible with this antibody when diluted?
   • Freezing is not recommended for NB100-417 under any circumstances. Unfortunately, the antibody would no longer be covered by our guarantee if it was stored at a temperature that did not match our storage instructions. Of course, you are free to test your proposed conditions if you would like, but we would not be able to accept responsibility if the antibody was damaged by this.
5. Is this antibody is carrier-free? If not, do you have a carrier-free version?
   • NB100-417 is carrier protein free, but does contain 0.1% sodium azide. The buffer formulation is: Tris-citrate/phosphate, pH 7-8 with 0.1% sodium azide. The following products are carrier protein and azide free (catalog numbers 23300002, H00000768-B01P and H00000768-D01P). If you would like to use NB100-417, we do offer antibody purification kits to remove unwanted buffer ingredients. See this link here for those products.
6. I have a couple of questions regarding the Carbonic Anhydrase IX Antibody (NB100-417) listed on your website. We are wondering if this antibody is carrier-free, and if not, whether you have a carrier-free version?
   • NB100-417 is carrier protein free but does contain 0.025% sodium azide. The buffer formulation is: PBS with 0.025% sodium azide. The following products are carrier protein and azide free (catalog numbers NBP2-34411, NBP2-34408, and NBP2-33152). If you would like to use NB100-417, we do offer antibody purification kits to remove unwanted buffer ingredients.
7. I am interested in using the CA9 antibody (NB100-417) that you supply. We dilute our antibodies in 5% milk TBS-Tween and usually freeze-thaw them multiple times. Is this possible with this antibody when diluted?
   • I have checked with the lab and they have informed me that freezing is not recommended for NB100-417 under any circumstances. Unfortunately, the antibody would no longer be covered by our guarantee if it was stored at a temperature that did not match our storage instructions. Of course, you are free to test your proposed conditions if you would like, but we would not be able to accept responsibility if the antibody was damaged by this.
8. Could this antibody (CA9) be safely stored at -80C?
   • The recommended storage temperature for NB100-417 is -20C. It may be possible to store this antibody at -80C, but this has not been confirmed by our lab. It is most important to ensure that that antibody does not undergo too many freeze-thaw cycles.
9. What is the predicted theoretical molecular weight of Carbonic Anhydrase IX/CA9 antibodies?
   • The TMW for Carbonic Anhydrase IX/CA9 antibodies is 50 kDa. Please note the observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Bioinformatics

• Gene Symbol: CA9